Inicio
Blood Advances
|
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (3)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaHealthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study / Kenny Mauricio Gálvez Cárdenas
Título : Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor Fecha de publicación : 2024 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Abstract: Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past two decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study (NCT03955900) of patients with MM in five Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged 18 years or older diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (N=339) and private (N=682) institutions. These two groups differed in many respects, with the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio=0.84; 95% confidence interval, 0.67 to 1.04; P=0.109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : ADV-2024-013838R2 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor . - 2024.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Abstract: Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past two decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study (NCT03955900) of patients with MM in five Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged 18 years or older diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (N=339) and private (N=682) institutions. These two groups differed in many respects, with the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio=0.84; 95% confidence interval, 0.67 to 1.04; P=0.109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : ADV-2024-013838R2 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002311 AC-2024-166 Archivo digital Producción Científica Artículos científicos Disponible
Título : Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor Fecha de publicación : 2024 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625 PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39729499/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor . - 2024.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Myelofibrosis (MF), a myeloproliferative neoplasm, was most commonly treated with hydroxyurea (HU) before approval of ruxolitinib (RUX), now the standard of care. Factors that influence real-world MF treatment patterns are not well understood. The METER study was a multi-country, retrospective chart review of MF treatment patterns, treatment effectiveness, and health care resource utilization. Of 997 eligible patients, 65.9% had primary MF, and 11.7% were transfusion dependent. Median time from diagnosis to the start of initial treatment (index date) was 29 days (interquartile range [IQR], 1-140). RUX was the most common first-line (1L) therapy (49.0%), followed by HU (40.2%); 48.5% of patients remained on 1L therapy through week 156. Seventy-seven patients underwent allogeneic stem cell transplantation; transplantation was uncommon at 1L, increasing from 2.2% at week 24 to 11.0% at week 156 in patients ?70 years of age. Median overall survival was 79.1 months (95% confidence interval [95% CI], 70.8 to not estimable [NE]) in all patients, 142.3 months (95% CI, 74.1 to NE) for non-RUX patients, 77.6 months (95% CI, 64.2-85.9) for patients on RUX 1L therapy, and 72.6 months (95% CI, 62.0 to NE) for RUX 2L+ patients. Of patients who experienced ?1 corresponding event, the median hospital length of stay (LoS; n = 520), intensive care unit LoS (n = 71), and number of transfusions (n = 375) were 16 days (IQR, 7-37), 5 days (IQR, 2-13), and 12 (IQR, 4-26), respectively. Despite improvements, there were numerous hospitalization and transfusion events among these patients in routine practice. This trial was registered at www.ClinicalTrials.gov as #NCT05444972. Mención de responsabilidad : Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. Referencia : Blood Adv . 2025 Mar 11;9(5):1105-1116. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024014625 PMID : 39729499 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39729499/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002316 AC-2024-171 Archivo digital Producción Científica Artículos científicos Disponible
Título : New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, Fecha de publicación : 2020 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT [documento electrónico] / Luz Natalia Builes Restrepo, . - 2020.
Obra : Blood Advances
Idioma : Inglés (eng)
Palabras clave : tissue microarray transplantation trimethylamine hematopoietic stem cell transplantation Resumen : This study aimed to identify a risk profile for development of transplant-associated thrombotic microangiopathy (TA-TMA) in children undergoing hematopoietic stem cell transplantation (HSCT). Between 2013 and 2016, 439 children underwent 474 HSCTs at 2 supraregional United Kingdom centers. At a median of 153 days post-HSCT, TA-TMA occurred among 25 of 441 evaluable cases (5.6%) with no evidence of center variation. Sex, underlying disease, intensity of the conditioning, total body irradiation–based conditioning, the use of calcineurin inhibitors, venoocclusive disease, and viral reactivation did not influence the development of TA-TMA. Donor type: matched sibling donor/matched family donor vs matched unrelated donor vs mismatched unrelated donor/haplo-HSCT, showed a trend toward the development of TA-TMA in 1.8% vs 6.1% vs 8.3%, respectively. Presence of active comorbidity was associated with an increased risk for TA-TMA; 13% vs 3.7% in the absence of comorbidity. The risk of TA-TMA was threefold higher among patients who received >1 transplant. TA-TMA rates were significantly higher among patients with acute graft-versus-host disease (aGVHD) grades III to IV vs aGVHD grade 0 to II. On multivariate analysis, the presence of active comorbidity, >1 transplant, aGVHD grade III to IV were risk factors for TA-TMA (odds ratio [OR]: 5.1, 5.2, and 26.9; respectively), whereas the use of cyclosporine A/tacrolimus-based GVHD prophylaxis was not a risk factor for TA-TMA (OR: 0.3). Active comorbidity, subsequent transplant, and aGVHD grades III to IV were significant risk factors for TA-TMA. TA-TMA might represent a form of a vascular GVHD, and therefore, continuing control of aGVHD is important to prevent worsening of TA-TMA associated with GVHD. Mención de responsabilidad : Reem Elfeky, Giovanna Lucchini, Su-Han Lum, Giorgio Ottaviano, Natalia Builes, Zohreh Nademi, Alexandra Battersby, Terence Flood, Stephen Owens, Andrew J Cant, Helen Young, Sinéad Greener, Patrick Walsh, David Kavanagh, Srinivas Annavarapu, Kanchan Rao, Persis Amrolia, Robert Chiesa, Austen Worth, Claire Booth, Roderick Skinner, Bilyana Doncheva, Joseph Standing, Andrew R Gennery, Waseem Qasim, Mary Slatter, Paul Veys Referencia : Blood Adv. 2020 Jun 9;4(11):2418-2429. DOI (Digital Object Identifier) : 10.1182/bloodadvances.2019001315 PMID : 32492158 En línea : https://ashpublications.org/bloodadvances/article/4/11/2418/460608/New-insights- [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001335 AC-2020-039 Archivo digital Producción Científica Artículos científicos Disponible
